These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25047979)

  • 1. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Newberry K; Pemmaraju N; Jabbour E; Zhou L; Pierce S; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2014 Sep; 38(9):1126-9. PubMed ID: 25047979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.
    Daver N; Shastri A; Kadia T; Quintas-Cardama A; Jabbour E; Konopleva M; O'Brien S; Pierce S; Zhou L; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2013 Nov; 37(11):1440-4. PubMed ID: 23890523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide is active in the treatment of anemia associated with myelofibrosis.
    Tefferi A; Verstovsek S; Barosi G; Passamonti F; Roboz GJ; Gisslinger H; Paquette RL; Cervantes F; Rivera CE; Deeg HJ; Thiele J; Kvasnicka HM; Vardiman JW; Zhang Y; Bekele BN; Mesa RA; Gale RP; Kantarjian HM
    J Clin Oncol; 2009 Sep; 27(27):4563-9. PubMed ID: 19652059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase-2 trial of low-dose pomalidomide in myelofibrosis.
    Begna KH; Mesa RA; Pardanani A; Hogan WJ; Litzow MR; McClure RF; Tefferi A
    Leukemia; 2011 Feb; 25(2):301-4. PubMed ID: 21052089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
    Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
    Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of pomalidomide therapy in myelofibrosis.
    Begna KH; Pardanani A; Mesa R; Litzow MR; Hogan WJ; Hanson CA; Tefferi A
    Am J Hematol; 2012 Jan; 87(1):66-8. PubMed ID: 22081489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
    Duan M; Zhou D
    Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
    Tefferi A; Hudgens S; Mesa R; Gale RP; Verstovsek S; Passamonti F; Cervantes F; Rivera C; Tencer T; Khan ZM
    Clin Ther; 2014 Apr; 36(4):560-6. PubMed ID: 24636526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
    Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
    Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis.
    Pardanani A; Begna K; Finke C; Lasho T; Tefferi A
    Am J Hematol; 2011 Apr; 86(4):343-5. PubMed ID: 21442636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
    Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
    Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
    Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
    Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
    Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
    J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase1/-2 study of Pomalidomide in myelofibrosis.
    Mesa RA; Pardanani AD; Hussein K; Wu W; Schwager S; Litzow MR; Hogan WJ; Tefferi A
    Am J Hematol; 2010 Feb; 85(2):129-30. PubMed ID: 20052748
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
    Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
    Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
    Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
    Larocca A; Montefusco V; Bringhen S; Rossi D; Crippa C; Mina R; Galli M; Marcatti M; La Verde G; Giuliani N; Magarotto V; Guglielmelli T; Rota-Scalabrini D; Omedé P; Santagostino A; Baldi I; Carella AM; Boccadoro M; Corradini P; Palumbo A
    Blood; 2013 Oct; 122(16):2799-806. PubMed ID: 23954889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
    Thapaliya P; Tefferi A; Pardanani A; Steensma DP; Camoriano J; Wu W; Geyer S; Mesa RA
    Am J Hematol; 2011 Jan; 86(1):96-8. PubMed ID: 21132732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of prednisone treatment for the anemia of myelofibrosis.
    Hernández-Boluda JC; Martínez-Trillos A; García-Gutiérrez V; Ferrer-Marín F; Xicoy B; Alvarez-Larrán A; Kerguelen A; Barba P; Gómez M; Herrera JC; Correa JG; Cervantes F
    Leuk Lymphoma; 2016; 57(1):120-4. PubMed ID: 25944376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
    Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; McMullin MF; Ribrag V; Schiller G; Vannucchi AM; Zhou D; Reiser D; Zhong J; Gale RP
    Leukemia; 2017 Apr; 31(4):896-902. PubMed ID: 27773929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.